

# Contents

<b>1</b>	<b>Emergence of Coronary Heart Disease as a Diagnosis</b>	<b>1</b>
1.1	In Osler's Textbook (1904)	1
1.2	First Reports of Coronary Thrombosis with Survival	2
1.3	Papers Appear in British Journals	3
1.4	Added to International List of Causes of Death (1930)	4
<b>2</b>	<b>Experimental Pathology in St. Petersburg</b>	<b>5</b>
2.1	Atherosclerosis Introduced as a Pathological Term	5
2.2	Pioneering Experimental Work 1908–1913 Feeding Cholesterol to Rabbits in St. Petersburg	5
2.3	Anitschkow Described His Work Further in 1933 American Monograph	6
2.4	Anitschkow's Early Rabbit Work Confirmed in Other Countries	7
2.5	Rabbits' Arterial Lesions Compared with Human Atherosclerosis	7
<b>3</b>	<b>Is Plasma Cholesterol Raised with Human Atherosclerosis?</b>	<b>9</b>
3.1	Cholesterol Characteristic in Human Atherosclerosis	9
3.2	At First Not Clear If Plasma Cholesterol Raised with Human Atherosclerosis	9
3.3	Improved Statistical Design Shows Average Plasma Cholesterol Higher with CHD	10
3.4	It Is Low-Density Lipoproteins that Are Associated with CHD	10
3.5	"Normal" Cholesterol Level in Affluent Countries May Not Be Healthy Cholesterol	11
3.6	Serum Cholesterols Lower in Naples and Madrid ... and Hunter Gatherers	11
<b>4</b>	<b>Diet <i>Can</i> Have Worthwhile Effects on Human Plasma Cholesterol</b>	<b>13</b>
4.1	Dietary Cholesterol	13
4.2	Dietary Fat Has More Effect than Dietary Cholesterol	14

- 4.3 And the Type of Dietary Fat . . . . . 14
  - 4.3.1 Saturated and Polyunsaturated Fats, Rather than Animal or Vegetable Fats . . . . . 14
  - 4.3.2 Repeated Tests by Keys' Group with Different Fats and Oils . . . . . 16
  - 4.3.3 Not All Saturated Fatty Acids Have the Same Effect on Serum Cholesterol . . . . . 17
- 4.4 How Does It Work? Could It Be by Changing Cholesterol Excretion? . . . . . 18
- 4.5 Discovery of the Low Density Lipoprotein Receptor . . . . . 18
- 5 A New Type of Observational Epidemiology . . . . . 21**
  - 5.1 Invention of Prospective, Cohort Studies . . . . . 21
    - 5.1.1 The Framingham Study, Started 1949 . . . . . 21
  - 5.2 Results Emerge from Framingham and Subsequent Cohort Studies . . . . . 22
    - 5.2.1 Big Three Risk Factors: Serum Cholesterol, Smoking and Blood Pressure . . . . . 22
  - 5.3 Tentative Recommendations to High Risk Patients Start in 1960s . . . . . 23
- 6 Serum Triglycerides? Another Risk Factor . . . . . 25**
  - 6.1 Endogenous and Exogenous Serum Triglycerides . . . . . 25
  - 6.2 Early Claims that Serum Triglycerides Predict Risk of CHD . . . . . 25
  - 6.3 Fasting Serum Triglycerides Not a Strong Independent Risk Factor . . . . . 26
- 7 Fredrickson's Classification of the Hyperlipoproteinaemias . . . . . 29**
  - 7.1 Five Types of Hyperlipidaemia, and Three Types of Low Serum Lipoproteins . . . . . 29
  - 7.2 Further Developments of Fredrickson's Types . . . . . 31
- 8 The Seven Countries Study (7CS) . . . . . 33**
  - 8.1 Setting Up . . . . . 33
  - 8.2 Methods . . . . . 35
    - 8.2.1 Results . . . . . 35
    - 8.2.2 Dietary Results . . . . . 36
  - 8.3 Implications from the 7CS . . . . . 37
  - 8.4 Longer Follow Up . . . . . 38
- 9 Sucrose – An Alternative Dietary Hypothesis . . . . . 39**
  - 9.1 Yudkin's Proposal . . . . . 39
  - 9.2 Reactions . . . . . 40
- 10 HDL-Cholesterol Is Protective . . . . . 41**
  - 10.1 Early Observations . . . . . 41
  - 10.2 The Millers' Hypothesis . . . . . 42
    - 10.2.1 It Ran Against the Grain . . . . . 42

10.3	Epidemiological Support . . . . .	42
10.4	HDL <sub>2</sub> or HDL <sub>3</sub> ? . . . . .	43
10.5	In Developing Countries? . . . . .	43
10.6	In Women . . . . .	43
10.7	Diet Affects HDL-Cholesterol Quite Differently . . . . .	44
<b>11</b>	<b>Critics and Sceptics . . . . .</b>	<b>45</b>
11.1	Sir John McMichael, London . . . . .	45
11.2	Dr George Mann, USA . . . . .	46
<b>12</b>	<b>Thrombosis on and in Atheroma . . . . .</b>	<b>49</b>
12.1	Thrombosis a Separate, Acute Process . . . . .	49
12.2	Tests for Liability to Thrombosis Are Indirect . . . . .	49
12.3	Or Can Mural Thrombosis Become Atheroma? . . . . .	50
<b>13</b>	<b>Dietary Cholesterol <i>May</i> Affect Plasma Cholesterol . . . . .</b>	<b>51</b>
13.1	Keys Had Asserted Dietary Cholesterol Does Not Raise Plasma Cholesterol . . . . .	51
13.2	Other Early Studies Inconclusive . . . . .	51
13.3	Keys' Group and Hegsted's Group Re-examine . . . . .	52
13.4	Metabolism of Labelled Cholesterol . . . . .	52
13.5	Many Human Experiments with Dietary Cholesterol 1960s and 1970s . . . . .	53
13.6	Are Some Individuals Responsive to Dietary Cholesterol, Not Others? . . . . .	54
13.7	Effect of Basal Cholesterol Intake . . . . .	55
13.8	Different Recommendations by Advisory Committees . . . . .	56
<b>14</b>	<b>First Controlled Trials . . . . .</b>	<b>57</b>
14.1	First Two Randomised Dietary Trials, 1965 . . . . .	57
14.2	Two More Dietary Trials . . . . .	58
14.3	The Los Angeles VA Trial, Reported 1969 . . . . .	59
14.4	Helsinki Mental Hospitals . . . . .	59
14.5	Drugs Trials . . . . .	61
14.5.1	Early Trials with Cholesterol-Lowering Drugs . . . . .	61
14.5.2	More Promising Drugs Followed . . . . .	61
14.5.3	"Atromid" or Clofibrate . . . . .	62
14.5.4	Cholestyramine Resin . . . . .	62
<b>15</b>	<b>Dietary Fibre . . . . .</b>	<b>63</b>
<b>16</b>	<b>Obesity . . . . .</b>	<b>65</b>
16.1	Desirable Weight for Height . . . . .	65
16.2	Body Mass Index . . . . .	66
16.3	Waist Circumference – Visceral Adiposity . . . . .	69
16.4	At the End of the Century the Cardiac Risk of Overweight Remained Variable for Moderate Overweight . . . . .	70

<b>17</b>	<b>Thrombosis Treated Early</b> . . . . .	71
17.1	Acute Phase Coronary Angiography . . . . .	71
17.2	Clotting Factors in a Prospective Study . . . . .	72
17.3	Platelet Function . . . . .	73
	Box 17.1 What's a Normal Plasma Cholesterol? . . . . .	74
<b>18</b>	<b>Fish Oil</b> . . . . .	77
18.1	Traditional Eskimos: High Fat Diet but CHD Uncommon . . . . .	77
18.2	Eicosapentaenoic Acid Reduces Platelet Aggregation . . . . .	78
18.3	Epidemiological Studies: Fish Consumption and CHD . . . . .	79
18.4	Polyunsaturated Oils Prevent Dangerous Arrhythmias in Rats . . . . .	80
18.5	Human Prevention Trials with Fish Oil . . . . .	81
<b>19</b>	<b>Alcohol</b> . . . . .	83
19.1	Impressions at Post-mortem Examination . . . . .	83
19.2	Negative Association with CHD in 1974 Case-Control Study . . . . .	84
19.3	Epidemiological Studies Build Up the Case . . . . .	84
19.4	Alcohol Only Benefits Health of Older People in Developed Countries . . . . .	86
19.5	Which Type of Alcoholic Drink? . . . . .	87
19.6	How Does Alcohol Reduce the Risk of CHD? . . . . .	88
	19.6.1 Serum HDL-Cholesterol (HDL-c) . . . . .	88
	19.6.2 Haemostatic Effects . . . . .	89
	19.6.3 Polyphenolic Antioxidants in the Beverage . . . . .	89
19.7	The French Paradox . . . . .	89
<b>20</b>	<b>Coffee</b> . . . . .	91
20.1	Coffee and Caffeine . . . . .	91
20.2	Coffee and CHD (Direct) Epidemiology . . . . .	92
	20.2.1 Coffee and Serum Cholesterol: Human Experiments . . . . .	93
	20.2.2 It's Cafestol and Kahweol in Coffee that Raise Serum Cholesterol . . . . .	94
20.3	And Tea? . . . . .	95
<b>21</b>	<b>Trans-Fatty Acids</b> . . . . .	97
21.1	Hydrogenation of Liquid Oils to Make Solid Margarines . . . . .	97
21.2	Human Experiments: Trans Fatty Acids and Serum Cholesterol . . . . .	98
21.3	Epidemiological Studies . . . . .	101
21.4	Conclusion . . . . .	102
<b>22</b>	<b>Antioxidants</b> . . . . .	103
22.1	LDL Oxidation and Atherosclerosis – Hypothesis . . . . .	103
22.2	$\alpha$ -Tocopherol the Major Antioxidant Inside LDL . . . . .	104
22.3	Vitamin E and CHD in Cohort Studies . . . . .	104

22.4	Randomised Controlled Prevention Trials with Vitamin E . . .	105
22.5	Trials with Beta-Carotene . . . . .	105
22.6	Why Didn't Alpha Tocopherol or Beta Carotene Work? . . . .	106
	Box 22.2 Fruit and Vegetables – Part of Favourable Dietary Patterns .	106
<b>23</b>	<b>More Controlled Dietary Trials</b> . . . . .	<b>109</b>
23.1	Further Dietary Trials in Table 23.1 . . . . .	109
23.2	Two Large Multi-Factorial Trials . . . . .	112
23.3	Four Dietary Trials Assessed by Coronary Angiography . . . .	113
23.4	The Lyon Diet Heart Study . . . . .	114
<b>24</b>	<b>Trials of Better Drugs</b> . . . . .	<b>115</b>
24.1	Cholestyramine (1984) . . . . .	115
24.2	Gemfibrozil (1987) . . . . .	116
	24.2.1 Statins Arrive . . . . .	116
	24.2.2 Implications of Statins . . . . .	118
<b>25</b>	<b>Linoleic Acid Is Protective</b> . . . . .	<b>121</b>
25.1	Cohort Studies Accumulate . . . . .	121
25.2	Mechanism(s) of Action . . . . .	123
25.3	Linoleic (18:2) Not the Usual Source of Arachidonic Acid (20:4) . . . . .	123
25.4	Recommendations . . . . .	123
<b>26</b>	<b>Plant Sterols Fade and Return</b> . . . . .	<b>125</b>
26.1	Phytosterols Not Absorbed . . . . .	125
26.2	The Pharmaceutical Phase . . . . .	126
26.3	Sitosterolaemia . . . . .	127
26.4	The Food Additive Phase . . . . .	127
<b>27</b>	<b>Soy Proteins Versus Casein</b> . . . . .	<b>129</b>
27.1	An Animal Protein Effect on Serum Cholesterol in Rabbits . .	129
27.2	In Humans Soy Protein Compared Against Casein: Variable Results . . . . .	130
27.3	Isoflavones May Contribute . . . . .	131
<b>28</b>	<b>High Homocysteine Associated with Cardiovascular Diseases</b> . . .	<b>133</b>
28.1	Homocystinuria and Arterial Disease . . . . .	133
28.2	Raised Plasma Homocysteine and Arterial Disease . . . . .	134
28.3	Environmental Influences on Plasma Homocysteine . . . . .	135
28.4	Plasma Homocysteine Lowered by Folic Acid and/or Vitamin B-12 . . . . .	136
<b>29</b>	<b>And Salt Should Be Included</b> . . . . .	<b>139</b>
29.1	Discovery of Essential Hypertension . . . . .	139
29.2	Early Diets for Hypertension . . . . .	140
29.3	Is Salt a Cause of Essential Hypertension? . . . . .	142
29.4	Thiazides and Sceptics . . . . .	144
	Box 29.1 Potassium and Blood Pressure . . . . .	144

29.5	Answers to the Sceptics; the Salt Case Develops . . . . .	145
29.5.1	Moderate Sodium Restriction . . . . .	145
29.5.2	Remote Communities . . . . .	146
29.5.3	Regression Dilution Bias . . . . .	147
29.5.4	INTERSALT . . . . .	147
29.5.5	Chimpanzee Experiments . . . . .	148
29.5.6	Cardiac Effects of Salt Reduction . . . . .	149
Box 29.2	Higher Blood Pressures in African Americans . . . . .	149
29.6	Baby Food Manufacturers Take the Lead . . . . .	150
29.6.1	And for Adults . . . . .	151
29.6.2	Dietary Goals for the US . . . . .	151
29.6.3	Subsequent Official Recommendations . . . . .	152
29.7	Most Salt We Eat Was Put in by Food Processors . . . . .	152
29.8	How Does BP Increase in Salt-Sensitive Individuals . . . . .	153
29.8.1	Kidneys . . . . .	153
29.8.2	Arterioles . . . . .	153
29.8.3	Humoral Inhibitor of the Sodium Pump . . . . .	154
29.9	Into the Next Century . . . . .	155
<b>30</b>	<b>How It Adds Up . . . . .</b>	<b>157</b>
30.1	American Heart Association, 2000 . . . . .	157
30.2	In “ABC of Nutrition”, 1999 . . . . .	158
<b>31</b>	<b>The Big Picture . . . . .</b>	<b>161</b>
31.1	USA and Canada . . . . .	161
31.2	Australia and New Zealand (Fig. 31.4) . . . . .	164
31.3	Nordic Countries . . . . .	166
31.4	British Isles (Fig. 31.6) . . . . .	167
31.5	Western Europe . . . . .	168
31.6	East European Countries . . . . .	169
<b>32</b>	<b>End Notes . . . . .</b>	<b>173</b>
32.1	What Happened . . . . .	173
32.2	On the Research Front . . . . .	174
32.3	Inertia and Opposition . . . . .	175
32.4	In the Public Arena . . . . .	176
32.5	What Happened Further . . . . .	177
32.6	Hypothesis and Variations . . . . .	178
	<b>References . . . . .</b>	<b>181</b>
	<b>Index . . . . .</b>	<b>221</b>